United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,241 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total value of $160,026.95. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

United Therapeutics Corporation (UTHR) opened at $133.32 on Friday. United Therapeutics Corporation has a 12 month low of $112.01 and a 12 month high of $169.89. The stock has a market capitalization of $5,760.89, a P/E ratio of 11.76 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same period in the previous year, the company posted $4.23 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis. analysts anticipate that United Therapeutics Corporation will post 12.45 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HPM Partners LLC boosted its position in shares of United Therapeutics by 0.8% during the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares in the last quarter. First Allied Advisory Services Inc. boosted its position in shares of United Therapeutics by 0.4% during the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 19 shares in the last quarter. Synovus Financial Corp boosted its holdings in United Therapeutics by 1.2% in the second quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after acquiring an additional 69 shares in the last quarter. Ifrah Financial Services Inc. boosted its holdings in United Therapeutics by 1.7% in the second quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 76 shares in the last quarter. Finally, Alps Advisors Inc. boosted its holdings in United Therapeutics by 2.3% in the second quarter. Alps Advisors Inc. now owns 3,827 shares of the biotechnology company’s stock worth $496,000 after acquiring an additional 86 shares in the last quarter. Institutional investors own 99.83% of the company’s stock.

A number of equities analysts recently weighed in on UTHR shares. ValuEngine cut United Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 8th. Zacks Investment Research raised United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Oppenheimer reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Friday, September 8th. Cowen reaffirmed a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $95.00 price target on shares of United Therapeutics in a research note on Thursday, October 26th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $136.10.

WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/12/03/martine-a-rothblatt-sells-1241-shares-of-united-therapeutics-corporation-uthr-stock.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.